Smallpox

Smallpox

Biodefense Headlines – 30 November 2023

News Scan November 30, 2023

News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

Call for Experts: Smallpox Medical Countermeasures

Smallpox Vaccines: Bavarian Nordic Awarded Another Contract to Supply EU Strategic Reserve

Eradicating Smallpox with Speedboat Epidemiology

Treatments for Poxviruses May Already Exist in Licensed Drugs

Smallpox Countermeasures: U.S. Awards $138M to Siga Technologies for TPOXX

Poxvirus Proteins Enable Early Strike on Immune Defences

Targeting Poxviruses with Messenger RNA Technology

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

Poxvirus Research After Smallpox Eradication: New Findings With An Old Vaccine

A Family Drama: The Sexual Politics of Smallpox Vaccination in the Spanish Empire

BioFactura Funded $13M Contract Option for Smallpox Biodefense Therapeutic

Lessons for COVID-19 Pandemic from the Massive Public Health Effort to Eradicate Smallpox

Why Is a U.S. Biotech Making Synthetic Vaccinia Virus?

Phase 3 Trial of Modified Vaccinia Ankara as a Smallpox Vaccine

USAMRIID Study Leads to Approval of New Smallpox Vaccine

Why Do We Need a New Smallpox Vaccine?

BioFactura’s Smallpox Biodefense Therapeutic Awarded $67M BARDA Contract

Biodefense Headlines – 30 November 2023